CU20210088A7 - Compuestos derivados sustituidos de indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) - Google Patents
Compuestos derivados sustituidos de indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)Info
- Publication number
- CU20210088A7 CU20210088A7 CU2021000088A CU20210088A CU20210088A7 CU 20210088 A7 CU20210088 A7 CU 20210088A7 CU 2021000088 A CU2021000088 A CU 2021000088A CU 20210088 A CU20210088 A CU 20210088A CU 20210088 A7 CU20210088 A7 CU 20210088A7
- Authority
- CU
- Cuba
- Prior art keywords
- virus
- hbv
- indol
- active against
- substituted derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
<p>La presente invención se refiere, en general, a compuestos derivados sustituidos de indol-2-carboxamidas activas, útiles para prevenir o tratar la infección del virus de la hepatitis B de fórmula general (I)</p> <p>ESPACIO PARA LA FÓRMULA</p> <p>Específicamente, estos compuestos pueden inhibir la proteína o proteínas codificada (s) por el virus de la hepatitis B (VHB) o interferir con la función del ciclo de replicación del VHB. La invención se refiere asimismo a composiciones que comprenden estos compuestos y a procesos o intermedios para fabricarlos.</p>
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19172005 | 2019-04-30 | ||
EP19172398 | 2019-05-02 | ||
PCT/EP2020/061948 WO2020221826A1 (en) | 2019-04-30 | 2020-04-29 | Novel indole-2-carboxamides active against the hepatitis b virus (hbv) |
Publications (1)
Publication Number | Publication Date |
---|---|
CU20210088A7 true CU20210088A7 (es) | 2022-06-06 |
Family
ID=70391142
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2021000088A CU20210088A7 (es) | 2019-04-30 | 2020-04-29 | Compuestos derivados sustituidos de indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) |
Country Status (17)
Country | Link |
---|---|
US (1) | US20220306647A1 (es) |
EP (1) | EP3962914A1 (es) |
JP (1) | JP2022530522A (es) |
KR (1) | KR20220004131A (es) |
CN (1) | CN113767101A (es) |
AU (1) | AU2020267015A1 (es) |
BR (1) | BR112021021564A2 (es) |
CA (1) | CA3138643A1 (es) |
CL (1) | CL2021002799A1 (es) |
CU (1) | CU20210088A7 (es) |
EC (1) | ECSP21079317A (es) |
IL (1) | IL287278A (es) |
MX (1) | MX2021013085A (es) |
SG (1) | SG11202111236UA (es) |
TW (1) | TWI770501B (es) |
UY (1) | UY38682A (es) |
WO (1) | WO2020221826A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2021383832A1 (en) | 2020-11-23 | 2023-06-22 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
US12006291B2 (en) | 2022-01-11 | 2024-06-11 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of 4,6,7-trifluoro-1H-indole-2-carboxylic acid |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19817264A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Neue Dihydropyrimidine |
WO2000058302A1 (de) | 1999-03-25 | 2000-10-05 | Bayer Aktiengesellschaft | Dihydropyrimidine und ihre verwendung zur behandlung von hepatitis b |
EP1189501B1 (en) | 1999-04-23 | 2007-02-28 | Extenday IP Limited | Sheet fastening and anchoring component |
WO2001045712A1 (de) | 1999-12-22 | 2001-06-28 | Bayer Aktiengesellschaft | Arzneimittelkombinationen gegen virale erkrankungen |
WO2005120516A2 (en) | 2004-06-09 | 2005-12-22 | Merck & Co., Inc. | Hiv integrase inhibitors |
WO2006033995A2 (en) | 2004-09-16 | 2006-03-30 | Valeant Research And Development | Thiazolidin-4-ones having anti-hepatitis b activity |
WO2013006394A1 (en) | 2011-07-01 | 2013-01-10 | Institute For Hepatitis And Virus Research | Sulfamoylbenzamide derivatives as antiviral agents against hbv infection |
CA2857344C (en) | 2011-12-21 | 2019-02-12 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
EP2800742B1 (en) | 2012-01-06 | 2016-04-06 | Janssen Sciences Ireland UC | 4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis b |
US9096579B2 (en) * | 2012-04-20 | 2015-08-04 | Boehringer Ingelheim International Gmbh | Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments |
DK2890683T3 (en) | 2012-08-28 | 2017-01-30 | Janssen Sciences Ireland Uc | MERGED BICYCLIC SULFAMOYL DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B |
NZ743499A (en) | 2012-08-28 | 2019-09-27 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
WO2014184328A1 (en) | 2013-05-17 | 2014-11-20 | F. Hoffmann-La Roche Ag | 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
EP2997019B1 (en) | 2013-05-17 | 2018-08-08 | Janssen Sciences Ireland UC | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
TR201807090T4 (tr) | 2013-07-25 | 2018-06-21 | Janssen Sciences Ireland Uc | Glioksamid sübstitüeli pirrolamid deriveleri ve bunun hepatitin tedavisine yönelik ilaçlar olarak kullanımı. |
AU2014337298B2 (en) | 2013-10-18 | 2018-12-06 | Indiana University Research And Technology Corporation | Hepatitis B viral assembly effectors |
KR20160127714A (ko) | 2013-11-14 | 2016-11-04 | 노비라 테라퓨틱스, 인코포레이티드 | 아제판 유도체 및 b형 간염 감염의 치료 방법 |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
JP6306750B2 (ja) | 2014-03-07 | 2018-04-04 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | B型肝炎ウイルス感染症の治療および予防のための新規な6−縮合ヘテロアリールジヒドロピリミジン |
RS59430B1 (sr) | 2014-03-13 | 2019-11-29 | Univ Indiana Res & Tech Corp | Alosterni modulatori proteina jezgra hepatitisa b |
SG11201605896WA (en) | 2014-03-28 | 2016-08-30 | Sunshine Lake Pharma Co Ltd | Dihydropyrimidine compounds and their application in pharmaceuticals |
CA2948580A1 (en) | 2014-05-09 | 2015-11-12 | Adam Zlotnick | Methods and compositions for treating hepatitis b virus infections |
CN106573898B (zh) | 2014-08-14 | 2018-11-09 | 豪夫迈·罗氏有限公司 | 治疗和预防乙型肝炎病毒感染的新的哒嗪酮和三嗪酮 |
AU2015358561A1 (en) | 2014-12-02 | 2017-06-08 | Novira Therapeutics, Inc. | Sulfide alkyl and pyridyl reverse sulfonamide compounds for HBV treatment |
US9518057B2 (en) | 2014-12-30 | 2016-12-13 | Novira Therapeutics, Inc. | Derivatives and methods of treating hepatitis B infections |
MA41338B1 (fr) | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Composés de pyrazine pour le traitement de maladies infectieuses |
CA2979490C (en) | 2015-03-16 | 2023-07-18 | F. Hoffmann-La Roche Ag | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor |
WO2016161268A1 (en) | 2015-04-01 | 2016-10-06 | Enanta Pharmaceuticals, Inc. | Hepatitis b antviral agents |
CN107922377A (zh) | 2015-04-17 | 2018-04-17 | 美国印第安纳大学研究和技术公司 | 乙肝病毒组装效应子 |
CN107624113B (zh) | 2015-05-04 | 2020-10-23 | 豪夫迈·罗氏有限公司 | 作为HBsAg (HBV 表面抗原)和HBV DNA 生成的抑制剂用于治疗乙型肝炎病毒感染的四氢吡啶并嘧啶和四氢吡啶并吡啶类化合物 |
WO2016183266A1 (en) | 2015-05-13 | 2016-11-17 | Enanta Pharmaceuticals, Inc. | Ehpatitis b antiviral agents |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10179131B2 (en) | 2015-07-13 | 2019-01-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
WO2017013046A1 (en) | 2015-07-21 | 2017-01-26 | F. Hoffmann-La Roche Ag | Novel tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection |
WO2017015451A1 (en) | 2015-07-22 | 2017-01-26 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
TW201720802A (zh) | 2015-09-15 | 2017-06-16 | 艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
CN108430971A (zh) | 2015-09-29 | 2018-08-21 | 诺维拉治疗公司 | 乙型肝炎抗病毒剂的晶体形式 |
WO2017076286A1 (zh) | 2015-11-04 | 2017-05-11 | 南京明德新药研发股份有限公司 | 二氢吡啶并环化合物的晶型、制备方法和中间体 |
US10280175B2 (en) | 2016-02-02 | 2019-05-07 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
CN109069488B (zh) | 2016-03-07 | 2021-09-07 | 英安塔制药有限公司 | 乙型肝炎抗病毒剂 |
DK3441389T3 (da) | 2016-04-06 | 2021-11-08 | Shanghai Zhimeng Biopharma Inc | Pyrazol-oxazolidinonforbindelse mod anti-hepatitis b-virus |
CN109153682B (zh) | 2016-05-20 | 2021-05-25 | 豪夫迈·罗氏有限公司 | 用于治疗感染性疾病的具有氧、硫和氮连接基的新的吡嗪化合物 |
MA45550A (fr) * | 2016-06-29 | 2019-05-08 | Novira Therapeutics Inc | Dérivés de diazépinone et leur utilisation dans le traitement des infections par l'hépatite b |
WO2018011160A1 (en) | 2016-07-14 | 2018-01-18 | F. Hoffmann-La Roche Ag | 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases |
CN109415368B (zh) | 2016-07-14 | 2021-04-30 | 豪夫迈·罗氏有限公司 | 用于治疗感染性疾病的羧基6,7-二氢-4H-吡唑并[1,5-a]吡嗪化合物 |
JP7051804B2 (ja) * | 2016-07-14 | 2022-04-11 | エフ.ホフマン-ラ ロシュ アーゲー | 感染症の治療のための6,7-ジヒドロ-4H-ピラゾロ[1,5-a]ピラジン化合物と6,7-ジヒドロ-4H-トリアゾロ[1,5-a]ピラジン化合物 |
JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
CA3036245C (en) | 2016-09-13 | 2021-07-20 | Arbutus Biopharma Corporation | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same |
EP3589630B1 (en) | 2017-03-02 | 2021-07-07 | Assembly Biosciences, Inc. | Cyclic sulfamide compounds and methods of using same |
EP3601216B1 (en) | 2017-03-21 | 2023-10-25 | Arbutus Biopharma Corporation | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same for the treatment of hepatitis b virus infection |
JP7123429B2 (ja) | 2017-05-04 | 2022-08-23 | シャンハイ ロングウッド バイオファルマシューティカルズ カンパニー リミテッド | 二環式縮合環系ヌクレオカプシド阻害剤および薬物としてb型肝炎を治療するためのその使用 |
CN109952305B (zh) | 2017-07-27 | 2022-06-21 | 江苏恒瑞医药股份有限公司 | 哌嗪并杂芳基类衍生物、其制备方法及其在医药上的应用 |
TW201912153A (zh) | 2017-08-30 | 2019-04-01 | 加拿大商愛彼特生物製藥公司 | 用於治療b型肝炎的化合物、醫藥組合物及方法 |
US10759774B2 (en) | 2017-09-28 | 2020-09-01 | The Curators Of The University Of Missouri | Inhibitors of hepatitis B virus targeting capsid assembly |
KR20200083551A (ko) * | 2017-11-02 | 2020-07-08 | 아이쿠리스 게엠베하 운트 코. 카게 | B형 간염 바이러스 (hbv)에 활성인 신규 고활성 아미노-티아졸 치환된 인돌-2-카르복스아미드 |
BR112020008765A2 (pt) * | 2017-11-02 | 2020-10-20 | Aicuris Gmbh & Co. Kg | indol-2-carboxamidas pirazolo-piperidina substituídas altamente ativas inovadoras ativas contra o vírus da hepatite b (hbv) |
-
2020
- 2020-04-29 WO PCT/EP2020/061948 patent/WO2020221826A1/en unknown
- 2020-04-29 AU AU2020267015A patent/AU2020267015A1/en not_active Abandoned
- 2020-04-29 MX MX2021013085A patent/MX2021013085A/es unknown
- 2020-04-29 BR BR112021021564A patent/BR112021021564A2/pt not_active IP Right Cessation
- 2020-04-29 KR KR1020217038545A patent/KR20220004131A/ko unknown
- 2020-04-29 EP EP20720857.0A patent/EP3962914A1/en not_active Withdrawn
- 2020-04-29 JP JP2021564278A patent/JP2022530522A/ja active Pending
- 2020-04-29 SG SG11202111236UA patent/SG11202111236UA/en unknown
- 2020-04-29 CU CU2021000088A patent/CU20210088A7/es unknown
- 2020-04-29 US US17/607,605 patent/US20220306647A1/en active Pending
- 2020-04-29 CN CN202080032420.1A patent/CN113767101A/zh active Pending
- 2020-04-29 CA CA3138643A patent/CA3138643A1/en active Pending
- 2020-04-30 TW TW109114654A patent/TWI770501B/zh active
- 2020-05-04 UY UY0001038682A patent/UY38682A/es unknown
-
2021
- 2021-10-14 IL IL287278A patent/IL287278A/en unknown
- 2021-10-25 CL CL2021002799A patent/CL2021002799A1/es unknown
- 2021-10-26 EC ECSENADI202179317A patent/ECSP21079317A/es unknown
Also Published As
Publication number | Publication date |
---|---|
MX2021013085A (es) | 2021-11-17 |
WO2020221826A1 (en) | 2020-11-05 |
SG11202111236UA (en) | 2021-11-29 |
BR112021021564A2 (pt) | 2022-01-04 |
AU2020267015A1 (en) | 2021-12-23 |
US20220306647A1 (en) | 2022-09-29 |
EP3962914A1 (en) | 2022-03-09 |
JP2022530522A (ja) | 2022-06-29 |
CN113767101A (zh) | 2021-12-07 |
IL287278A (en) | 2021-12-01 |
ECSP21079317A (es) | 2021-11-30 |
TWI770501B (zh) | 2022-07-11 |
TW202106687A (zh) | 2021-02-16 |
CA3138643A1 (en) | 2020-11-05 |
CL2021002799A1 (es) | 2022-06-10 |
UY38682A (es) | 2020-11-30 |
KR20220004131A (ko) | 2022-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020004838A (es) | Nuevas indol-2-carboxamidas sustituidas con pirazolopiperidina, de alta actividad, activas contra el virus de la hepatitis b (vhb). | |
MX2020004839A (es) | Nuevas indol-2-carboxamidas sustituidas con amino-tiazol, de alta actividad, activas contra el virus de la hepatitis b (vhb). | |
CL2020000487A1 (es) | Agentes antivirales contra la hepatitis b. | |
UY38434A (es) | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv) | |
CU20210037A7 (es) | Compuestos derivados sustituidos de urea 6,7-dihidro-4h-pirazolo [1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb) | |
CL2021001117A1 (es) | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) | |
CU20210088A7 (es) | Compuestos derivados sustituidos de indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) | |
ECSP21078893A (es) | Nuevas fenil y piridil ureas activas contra el virus de la hepatitis b (vhb) | |
UY38435A (es) | Nuevas urea 6,7-dihidro-4h-pirazol[1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb) | |
CU20210090A7 (es) | Compuestos derivados de oxalil piperazinas activos contra el virus de la hepatitis b (vhb) | |
UY38439A (es) | Novedosas urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb) | |
UY38681A (es) | Nuevas indolizina-2-carboxamidas activas contra el virus de la hepatitis b (vhb) | |
EA202192967A1 (ru) | Новые индол-2-карбоксамиды, активные против вируса гепатита b (вгв) | |
EA202192969A1 (ru) | Новые оксалилпиперазины, активные против вируса гепатита b (вгв) | |
EA202192968A1 (ru) | Новые фенил- и пиридилмочевины, активные против вируса гепатита b (вгв) | |
EA202192965A1 (ru) | Новые индолизин-2-карбоксамиды, активные против вируса гепатита b (вгв) |